BRIEF published on 02/20/2026 at 21:42, 1 month ago Teva's Olanzapine Injectable Suspension Gains FDA Nod Schizophrenia Olanzapine Teva Pharmaceuticals FDA Acceptance Long-acting Injectable
PRESS RELEASE published on 02/20/2026 at 21:37, 1 month ago Inside Information / Other news releases FDA accepts Teva's NDA for once-monthly olanzapine for schizophrenia treatment, addressing treatment gap. Teva and Medincell collaborate for innovative solution FDA Schizophrenia Medincell Olanzapine Teva
BRIEF published on 02/19/2026 at 10:33, 1 month 2 days ago Mirova crosses a threshold at MEDINCELL Euronext Paris Voting Rights Transfer Of Shares Mirova MEDICELL
BRIEF published on 12/09/2025 at 14:55, 3 months 11 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 3 months 11 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 3 months 11 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 4 months 10 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 4 months 10 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 4 months 15 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 4 months 15 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
Published on 03/20/2026 at 21:15, 15 hours 56 minutes ago Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 23 hours 41 minutes ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 1 day ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/20/2026 at 22:45, 14 hours 26 minutes ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 16 hours 6 minutes ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 16 hours 6 minutes ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 16 hours 11 minutes ago BRP Unveils the Winners of its 6th International Design Challenge
Published on 03/20/2026 at 20:05, 17 hours 6 minutes ago INVESTOR ALERT: Goeasy Ltd. Shareholder Class Action
Published on 03/20/2026 at 19:00, 18 hours 11 minutes ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 18 hours 56 minutes ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 16:57, 20 hours 14 minutes ago Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 1 day 19 hours ago Filing of the 2025 Universal Registration Document
